SCM
AXSM icon

Segantii Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Segantii Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-7,800
Closed -$68K – 29
2016
Q1 		$68K Buy
+7,800
New +$71.6K 0.03% 153

Other funds holding AXSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Segantii Capital Management's AXSM Position: Q2 2016 in Review

Segantii Capital Management sold out of Axsome Therapeutics (AXSM) in Q2 2016, closing a stake of 7,800 shares — an estimated $68K sold.

Segantii Capital Management first reported a position in AXSM in Q1 2016 and held it in 1 quarter. The position peaked at $68K in Q1 2016. 34 funds tracked by Wall St. Rank hold AXSM as of Q2 2016.

  • Segantii Capital Management reported no remaining Axsome Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Segantii Capital Management sold 7,800 Axsome Therapeutics shares in Q2 2016, an estimated $68K.
  • Segantii Capital Management first reported a position in Axsome Therapeutics in Q1 2016 and held it in 1 quarter.
  • Segantii Capital Management's Axsome Therapeutics position peaked at $68K in Q1 2016.
  • 34 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2016.

Based on Segantii Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.